Literature DB >> 35373074

eGFR Decline after SGLT2 Inhibitor Initiation: The Tortoise and the Hare Reimagined.

Alejandro Y Meraz-Muñoz1, Jordan Weinstein1, Ron Wald1,2.   

Abstract

Entities:  

Keywords:  AKI; SGLT2i; acute kidney injury; clinical nephrology; eGFR; glomerular filtration rate; tubuloglomerular feedback

Mesh：

Substances：

Year:  2021        PMID： 35373074      PMCID： PMC8791377          DOI： 10.34067/KID.0001172021

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  28 in total

1.  Refining predictive models in critically ill patients with acute renal failure.

Authors:  Ravindra L Mehta; Maria T Pascual; Carmencita G Gruta; Shunping Zhuang; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2002-05       Impact factor: 10.121

2.  Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease.

Authors:  Dick de Zeeuw; Tadao Akizawa; Paul Audhya; George L Bakris; Melanie Chin; Heidi Christ-Schmidt; Angie Goldsberry; Mark Houser; Melissa Krauth; Hiddo J Lambers Heerspink; John J McMurray; Colin J Meyer; Hans-Henrik Parving; Giuseppe Remuzzi; Robert D Toto; Nosratola D Vaziri; Christoph Wanner; Janet Wittes; Danielle Wrolstad; Glenn M Chertow
Journal:  N Engl J Med       Date:  2013-11-09       Impact factor: 91.245

3.  Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.

Authors:  John J V McMurray; Scott D Solomon; Silvio E Inzucchi; Lars Køber; Mikhail N Kosiborod; Felipe A Martinez; Piotr Ponikowski; Marc S Sabatine; Inder S Anand; Jan Bělohlávek; Michael Böhm; Chern-En Chiang; Vijay K Chopra; Rudolf A de Boer; Akshay S Desai; Mirta Diez; Jaroslaw Drozdz; Andrej Dukát; Junbo Ge; Jonathan G Howlett; Tzvetana Katova; Masafumi Kitakaze; Charlotta E A Ljungman; Béla Merkely; Jose C Nicolau; Eileen O'Meara; Mark C Petrie; Pham N Vinh; Morten Schou; Sergey Tereshchenko; Subodh Verma; Claes Held; David L DeMets; Kieran F Docherty; Pardeep S Jhund; Olof Bengtsson; Mikaela Sjöstrand; Anna-Maria Langkilde
Journal:  N Engl J Med       Date:  2019-09-19       Impact factor: 91.245

Review 4.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.

Authors:  Hiddo J L Heerspink; Bruce A Perkins; David H Fitchett; Mansoor Husain; David Z I Cherney
Journal:  Circulation       Date:  2016-07-28       Impact factor: 29.690

5.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Stephen D Wiviott; Itamar Raz; Marc P Bonaca; Ofri Mosenzon; Eri T Kato; Avivit Cahn; Michael G Silverman; Thomas A Zelniker; Julia F Kuder; Sabina A Murphy; Deepak L Bhatt; Lawrence A Leiter; Darren K McGuire; John P H Wilding; Christian T Ruff; Ingrid A M Gause-Nilsson; Martin Fredriksson; Peter A Johansson; Anna-Maria Langkilde; Marc S Sabatine
Journal:  N Engl J Med       Date:  2018-11-10       Impact factor: 91.245

6.  Diabetic Kidney Disease: Challenges, Progress, and Possibilities.

Authors:  Radica Z Alicic; Michele T Rooney; Katherine R Tuttle
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-18       Impact factor: 8.237

7.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.

Authors:  Bruce Neal; Vlado Perkovic; Kenneth W Mahaffey; Dick de Zeeuw; Greg Fulcher; Ngozi Erondu; Wayne Shaw; Gordon Law; Mehul Desai; David R Matthews
Journal:  N Engl J Med       Date:  2017-06-12       Impact factor: 91.245

8.  Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy.

Authors:  C E Mogensen
Journal:  Scand J Clin Lab Invest       Date:  1986-05       Impact factor: 1.713

9.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.

Authors:  George L Bakris; Rajiv Agarwal; Stefan D Anker; Bertram Pitt; Luis M Ruilope; Peter Rossing; Peter Kolkhof; Christina Nowack; Patrick Schloemer; Amer Joseph; Gerasimos Filippatos
Journal:  N Engl J Med       Date:  2020-10-23       Impact factor: 91.245

10.  Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.

Authors:  Milton Packer; Stefan D Anker; Javed Butler; Gerasimos Filippatos; Stuart J Pocock; Peter Carson; James Januzzi; Subodh Verma; Hiroyuki Tsutsui; Martina Brueckmann; Waheed Jamal; Karen Kimura; Janet Schnee; Cordula Zeller; Daniel Cotton; Edimar Bocchi; Michael Böhm; Dong-Ju Choi; Vijay Chopra; Eduardo Chuquiure; Nadia Giannetti; Stefan Janssens; Jian Zhang; Jose R Gonzalez Juanatey; Sanjay Kaul; Hans-Peter Brunner-La Rocca; Bela Merkely; Stephen J Nicholls; Sergio Perrone; Ileana Pina; Piotr Ponikowski; Naveed Sattar; Michele Senni; Marie-France Seronde; Jindrich Spinar; Iain Squire; Stefano Taddei; Christoph Wanner; Faiez Zannad
Journal:  N Engl J Med       Date:  2020-08-28       Impact factor: 176.079
View more
  5 in total

1.  Selonsertib Enhances Kidney Protection Beyond Standard of Care in a Hypertensive, Secondary Glomerulosclerosis CKD Model.

Authors:  Shawn S Badal; Tareq Al Tuhaifi; Ya-Fen Yu; David Lopez; Craig T Plato; Kristin Joly; David G Breckenridge; Hai-Chun Yang; John T Liles; Agnes B Fogo
Journal:  Kidney360       Date:  2022-04-18

Review 2.  Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.

Authors:  Kevin Yau; Atit Dharia; Ibrahim Alrowiyti; David Z I Cherney
Journal:  Kidney Int Rep       Date:  2022-05-05

3.  Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.

Authors:  Sebastiaan Camiel Goulooze; Hiddo J L Heerspink; Martijn van Noort; Nelleke Snelder; Meike Brinker; Joerg Lippert; Thomas Eissing
Journal:  Clin Pharmacokinet       Date:  2022-05-05       Impact factor: 5.577

4.  Impact of COVID-19 on the worsening crisis of chronic kidney disease: the imperative to fund early detection is now.

Authors:  Karen M Dwyer; Caitlin Sum; David W Johnson
Journal:  Intern Med J       Date:  2022-03-06       Impact factor: 2.611

5.  A Description of Acute Renal Failure and Nephrolithiasis Associated With Sodium-Glucose Co-Transporter 2 Inhibitor Use: A VigiBase Study.

Authors:  Ioana Frent; Daniel Leucuta; Camelia Bucsa; Andreea Farcas; Florin Casoinic; Cristina Mogosan
Journal:  Front Pharmacol       Date:  2022-08-08       Impact factor: 5.988
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.